Genetic Insights into Lung Cancer Susceptibility through Whole Exome Analysis

Strategic Insights -

Research conducted by the Department of Medicine at the University of Rome, Italy, has shed light on the genetic factors contributing to lung cancer susceptibility. The study aimed to identify rare genetic variants associated with a higher risk of developing lung cancer in patients with a positive family history of the disease. Through exome sequencing, the researchers identified rare clinically significant variants and variants of unknown significance (VUS) in several well-known cancer genes, including POLE, PDGFRA, RTEL1, HNF1A, and MITF.

Key Takeaways:

  • The study found that germinal pathogenetic variants (GPV) in the EGFR and TP53 genes account for 0.34-0.9% and 0.8% of lung adenocarcinoma cases, respectively.
  • The researchers identified rare clinically significant variants and VUS in five well-known cancer genes in five patients, including one patient who carried three variants and was exposed to environmental risk factors such as smoking and asbestos.
  • The study also identified additional potentially clinically relevant rare variants in genes not previously associated with lung cancer, including HGS, NME4, HAPLN1, ATMIN, CEACAM, MEG1, USP4, TP53BP2, ERAP1, TNFAIP8L3, CASP1, MCC, SERPINA3, VIRMA, FOXK2, DNAH8, RASA2, and GLI3.
  • The researchers suggest that these newly identified genes deserve further investigation through segregation analysis, enlarged cohorts, and in vitro/in vivo studies to clarify their role in lung cancer.
  • The study highlights the importance of considering both environmental and genetic factors in the development of lung cancer.

Statistics:

  • 0.34-0.9% of lung adenocarcinoma cases are attributed to germinal pathogenetic variants in the EGFR gene.
  • 0.8% of lung adenocarcinoma cases are attributed to germinal pathogenetic variants in the TP53 gene.
  • 5 patients had rare clinically significant variants and VUS in well-known cancer genes.
  • 1 patient carried three variants and was exposed to environmental risk factors such as smoking and asbestos.
  • 21 genes were identified as potentially clinically relevant in lung cancer, including HGS, NME4, HAPLN1, ATMIN, CEACAM, MEG1, USP4, TP53BP2, ERAP1, TNFAIP8L3, CASP1, MCC, SERPINA3, VIRMA, FOXK2, DNAH8, RASA2, and GLI3.

Sources:

  • Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis. Lung Cancer, 2025;204:108560.
  • Department of Medicine Reports Findings in Lung Cancer (Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis). Ecology, Environment & Conservation. May 23, 2025; p 159.
  • NewsRx. Department of Medicine Reports Findings in Lung Cancer (Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis). Ecology, Environment & Conservation. May 23, 2025; p 159.